{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T05:58:52Z","timestamp":1763704732737},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.juro.2011.06.051","type":"journal-article","created":{"date-parts":[[2011,9,24]],"date-time":"2011-09-24T02:36:20Z","timestamp":1316831780000},"page":"2094-2100","source":"Crossref","is-referenced-by-count":33,"title":["Predictive Value of Microtubule Associated Proteins Tau and Stathmin in Patients With Nonmuscle Invasive Bladder Cancer Receiving Adjuvant Intravesical Taxane Therapy"],"prefix":"10.1097","volume":"186","author":[{"given":"Matthew S.","family":"Wosnitzer","sequence":"first","affiliation":[{"name":"Department of Urology, Columbia University College of Physicians and Surgeons, Columbia University, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep","family":"Domingo-Domenech","sequence":"additional","affiliation":[{"name":"Herbert Irving Comprehensive Cancer Center, Columbia University College of Physicians and Surgeons, Columbia University, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mireia","family":"Castillo-Martin","sequence":"additional","affiliation":[{"name":"Herbert Irving Comprehensive Cancer Center, Columbia University College of Physicians and Surgeons, Columbia University, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chad","family":"Ritch","sequence":"additional","affiliation":[{"name":"Department of Urology, Columbia University College of Physicians and Surgeons, Columbia University, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahesh","family":"Mansukhani","sequence":"additional","affiliation":[{"name":"Department of Pathology and Cell Biology, Columbia University College of Physicians and Surgeons, Columbia University, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel P.","family":"Petrylack","sequence":"additional","affiliation":[{"name":"Herbert Irving Comprehensive Cancer Center, Columbia University College of Physicians and Surgeons, Columbia University, New York, New York"},{"name":"Division of Hematology\/Oncology, Department of Medicine, Columbia University College of Physicians and Surgeons, Columbia University, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell C.","family":"Benson","sequence":"additional","affiliation":[{"name":"Department of Urology, Columbia University College of Physicians and Surgeons, Columbia University, New York, New York"},{"name":"Herbert Irving Comprehensive Cancer Center, Columbia University College of Physicians and Surgeons, Columbia University, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James M.","family":"McKiernan","sequence":"additional","affiliation":[{"name":"Department of Urology, Columbia University College of Physicians and Surgeons, Columbia University, New York, New York"},{"name":"Herbert Irving Comprehensive Cancer Center, Columbia University College of Physicians and Surgeons, Columbia University, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Cordon-Cardo","sequence":"additional","affiliation":[{"name":"Department of Urology, Columbia University College of Physicians and Surgeons, Columbia University, New York, New York"},{"name":"Herbert Irving Comprehensive Cancer Center, Columbia University College of Physicians and Surgeons, Columbia University, New York, New York"},{"name":"Department of Pathology and Cell Biology, Columbia University College of Physicians and Surgeons, Columbia University, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2011.06.051_bib1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","article-title":"Cancer statistics, 2009","volume":"59","author":"Jemal","year":"2009","journal-title":"J Clin"},{"key":"10.1016\/j.juro.2011.06.051_bib2","series-title":"World Health Organization Classification of Tumours","first-page":"359","article-title":"Pathology and genetics of tumours of the urinary system and male genital organs","author":"Eble","year":"2004"},{"key":"10.1016\/j.juro.2011.06.051_bib3","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2011.06.051_bib4","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.urology.2003.11.049","article-title":"Intravesical bacille Calmette-Gu\u00e9rin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression","volume":"63","author":"Bohle","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.juro.2011.06.051_bib5","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00005392-199707000-00017","article-title":"The treated natural history of high risk superficial bladder cancer: 15-year outcome","volume":"158","author":"Cookson","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2011.06.051_bib6","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0022-5347(05)65757-6","article-title":"Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed","volume":"166","author":"O'Donnell","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2011.06.051_bib7","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.eururo.2007.04.062","volume":"52","author":"Ojea","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2011.06.051_bib8","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1200\/JCO.2008.20.8199","article-title":"Randomized phase III trial on gemcitabine versus mitomycin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance","volume":"28","author":"Addeo","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2011.06.051_bib9","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","article-title":"Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder","volume":"163","author":"Steinberg","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2011.06.051_bib10","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1200\/JCO.2005.03.1161","article-title":"Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy","volume":"24","author":"McKiernan","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2011.06.051_bib11","doi-asserted-by":"crossref","first-page":"4542","DOI":"10.1200\/jco.2010.28.15_suppl.4542","article-title":"Phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of BCG-refractory non-muscle-invasive bladder cancer","volume":"28","author":"Barlow","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2011.06.051_bib12","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s10549-007-9724-3","article-title":"The prognostic value of Stathmin-1, S100A2, and SYK proteins in ER-positive primary breast cancer patients treated with adjuvant tamoxifen monotherapy: an immunohistochemical study","volume":"110","author":"Golouh","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.juro.2011.06.051_bib13","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1038\/sj.bjc.6603182","article-title":"Reduced tau expression in gastric cancer can identify candidates for successful Paclitaxel treatment","volume":"94","author":"Mimori","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.juro.2011.06.051_bib14","doi-asserted-by":"crossref","first-page":"8315","DOI":"10.1073\/pnas.0408974102","article-title":"Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer","volume":"102","author":"Rouzier","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.juro.2011.06.051_bib15","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1002\/cncr.24282","article-title":"Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel","volume":"115","author":"Su","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.juro.2011.06.051_bib16","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.eururo.2003.11.011","article-title":"Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1-S modulators (p53, p21Waf1, p27kip1, cyclin D1, and cyclin D3) and proliferation index (ki67-MIB1)","volume":"45","author":"Lopez-Beltran","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2011.06.051_bib17","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1073\/pnas.72.5.1858","article-title":"A protein factor essential for microtubule assembly","volume":"72","author":"Weingarten","year":"1975","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.juro.2011.06.051_bib18","doi-asserted-by":"crossref","first-page":"12910","DOI":"10.1073\/pnas.0402928101","article-title":"Tau induces cooperative Taxol binding to microtubules","volume":"101","author":"Ross","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.juro.2011.06.051_bib19","doi-asserted-by":"crossref","first-page":"35686","DOI":"10.1074\/jbc.274.50.35686","article-title":"The microtubule binding of Tau and high molecular weight Tau in apoptotic PC12 cells is impaired because of altered phosphorylation","volume":"274","author":"Davis","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.juro.2011.06.051_bib20","doi-asserted-by":"crossref","first-page":"8422","DOI":"10.1073\/pnas.87.21.8422","article-title":"Identification of nuclear tau isoforms in human neuroblastoma cells","volume":"87","author":"Loomis","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.juro.2011.06.051_bib21","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/jcb.20187","article-title":"The role of stathmin in the regulation of the cell cycle","volume":"93","author":"Rubin","year":"2004","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.juro.2011.06.051_bib22","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1002\/pros.20601","article-title":"Increased expression and differential phosphorylation of stathmin may promote prostate cancer progression","volume":"67","author":"Ghosh","year":"2007","journal-title":"Prostate"},{"key":"10.1016\/j.juro.2011.06.051_bib23","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/sj.bjc.6602991","article-title":"Overexpression of stathmin in oral squamous-cell carcinoma: correlation with tumour progression and poor prognosis","volume":"94","author":"Kouzu","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.juro.2011.06.051_bib24","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/path.2011","article-title":"Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma","volume":"209","author":"Yuan","year":"2006","journal-title":"J Pathol"},{"key":"10.1016\/j.juro.2011.06.051_bib25","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0092-8674(00)81871-1","article-title":"p53, the cellular gatekeeper for growth and division","volume":"88","author":"Levine","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.juro.2011.06.051_bib26","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1158\/0008-5472.CAN-09-2218","article-title":"Chemosensitivity profiles identify polymorphisms in the p53 network genes 14-3-3tau and CD44 that affect sarcoma incidence and survival","volume":"70","author":"Vazquez","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.juro.2011.06.051_bib27","doi-asserted-by":"crossref","first-page":"512.e1","DOI":"10.1016\/j.urology.2010.04.040","article-title":"Prognostic value of p53 and Ki-67 expression in intermediate-risk patients with nonmuscle-invasive bladder cancer receiving adjuvant intravesical mitomycin C therapy","volume":"76","author":"Seo","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.juro.2011.06.051_bib28","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0022-5347(05)64001-3","article-title":"Over expression of metallothionein predicts resistance of transitional cell carcinoma of bladder to intravesical mitomycin therapy","volume":"169","author":"Lynn","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2011.06.051_bib29","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1464-410X.2008.08342.x","article-title":"A chemosensitivity test to individualize intravesical treatment for non-muscle-invasive bladder cancer","volume":"104","author":"Gazzaniga","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2011.06.051_bib30","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/01.ju.0000063685.29339.24","article-title":"Effect of intravesical treatment of transitional cell carcinoma with bacillus Calmette-Guerin and mitomycin C on urinary survivin levels and outcome","volume":"170","author":"Hausladen","year":"2003","journal-title":"J Urol"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534711043266?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534711043266?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2011.06.051","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T02:22:52Z","timestamp":1651198972000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1016\/j.juro.2011.06.051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["10.1016\/j.juro.2011.06.051"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2011.06.051","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}